购物车
- 全部删除
- 您的购物车当前为空
GSK2193874 是口服有效的TRPV4选择性拮抗剂,作用于rTRPV4和hTRPV4的IC50分别为 2 nM 和 40 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
GSK2193874 是口服有效的TRPV4选择性拮抗剂,作用于rTRPV4和hTRPV4的IC50分别为 2 nM 和 40 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 297 | 现货 | |
2 mg | ¥ 438 | 现货 | |
5 mg | ¥ 625 | 现货 | |
10 mg | ¥ 1,120 | 现货 | |
25 mg | ¥ 1,980 | 现货 | |
50 mg | ¥ 3,870 | 现货 | |
100 mg | ¥ 5,630 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 947 | 现货 |
产品描述 | GSK2193874 was identified as a selective, orally active TRPV4 blocker. |
靶点活性 | TRPV4 (rat):2 nM (IC50), TRPV4 (human):40 nM (IC50) |
体外活性 | GSK2193874被确定为一种选择性、口服活性的TRPV4阻断剂,能够抑制通过重组TRPV4通道以及天然内皮TRPV4电流的Ca(2+)流入[1,2]。 |
体内活性 | 在分离的啮齿类和犬类肺部中,TRPV4阻断能够防止与升高的PVP相关联的增加的血管通透性和由此导致的肺水肿。在急性和慢性HF模型中,GSK2193874的预处理抑制了肺水肿的形成并提高了动脉氧合[2]。 |
动物实验 | Adult male Sprague-Dawley rats (n = 7 to 8 per group) were treated with vehicle (6% Cavitron) or GSK2193874 (30 mg/kg/day) via oral gavage for at least 4 days before osmotic challenges.?Rats underwent acute and chronic hyper- and hypo-osmotic challenges.Sprague-Dawley (control, n = 18) and spontaneously hypertensive rats (n = 11) were implanted with Data Sciences International (DSI) radiotelemetry transmitters.?Rats were dosed with GSK2193874, and data were captured with DSI receivers and analyzed with Microsoft Excel[2]. |
分子量 | 691.62 |
分子式 | C37H38BrF3N4O |
CAS No. | 1336960-13-4 |
Smiles | FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1 |
密度 | 1.43 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 100 mg/mL (144.59 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容